Literature DB >> 12894066

Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.

Phoebe Rich1, Richard K Scher.   

Abstract

The Nail Psoriasis Severity Index (NAPSI) is a numeric, reproducible, objective, simple tool for evaluation of nail psoriasis. This scale is used to evaluate the severity of nail bed psoriasis and nail matrix psoriasis by area of involvement in the nail unit. The NAPSI will be useful during clinical trials for evaluating response to treatment of psoriatic nails. The scale is reproducible, and because there are few data points, statistical analysis is simplified.

Entities:  

Mesh：

Year:  2003        PMID： 12894066     DOI： 10.1067/s0190-9622(03)00910-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  83 in total

Review 1.  [A decade of biologics in dermatology].

Authors:  G Wozel; M Meurer
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

2.  The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis.

Authors:  Gamze Serarslan; Hayal Güler; Sinem Karazincir
Journal:  Clin Rheumatol       Date:  2006-11-22       Impact factor: 2.980

3.  To what extend is nail ultrasound discriminative between psoriasis, psoriatic arthritis and healthy subjects?

Authors:  Esperanza Naredo; Iustina Janta; Ofelia Baniandrés-Rodríguez; Lara Valor; Michelle Hinojosa; Natalia Bello; Belén Serrano; Jesús Garrido
Journal:  Rheumatol Int       Date:  2018-12-10       Impact factor: 2.631

4.  Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Authors:  Peter Foley; Kenneth Gordon; Christopher E M Griffiths; Yasmine Wasfi; Bruce Randazzo; Michael Song; Shu Li; Yaung-Kaung Shen; Andrew Blauvelt
Journal:  JAMA Dermatol       Date:  2018-06-01       Impact factor: 10.282

5.  Patient-relevant needs and treatment goals in nail psoriasis.

Authors:  C Blome; A Costanzo; E Dauden; C Ferrandiz; G Girolomoni; R Gniadecki; L Iversen; A Menter; K Michaelis-Wittern; A Morita; H Nakagawa; K Reich; M Augustin
Journal:  Qual Life Res       Date:  2015-10-03       Impact factor: 4.147

6.  Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.

Authors:  Dylan Haynes; Jennifer L Strunck; Christina A Topham; Alex G Ortega-Loayza; Gail Kent; Pamela B Cassidy; Ronghua Hu; Keith Choate; Zhiping Wang; Yuangang Liu; Teri M Greiling
Journal:  JAMA Dermatol       Date:  2020-06-01       Impact factor: 10.282

7.  A Comparison of The Effects of Clobetasol 0.05% and Photodynamic Therapy Using Aminolevulinic Acid With Red Light in the Treatment of Severe Nail Psoriasis.

Authors:  Zohreh Tehranchinia; Nasibeh Barzkar; Seyed Mohammad Riahi; Marjan Khazan
Journal:  J Lasers Med Sci       Date:  2020-01-18

8.  Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.

Authors:  María Denise Takahashi; Edgardo Néstor Chouela; Gladys Leon Dorantes; Ana Maria Roselino; Jesùs Santamaria; Miguel Angel Allevato; Tania Cestari; Maria Eugenia Manzanera de Aillaud; Fernando Miguel Stengel; Daiana Licu
Journal:  Arch Drug Inf       Date:  2010-03

9.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Authors:  Martin Rudwaleit; Filip Van den Bosch; Martina Kron; Sonja Kary; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

10.  Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.

Authors:  F Van den Bosch; B Manger; P Goupille; N McHugh; E Rødevand; P Holck; R F van Vollenhoven; M Leirisalo-Repo; O Fitzgerald; M Kron; M Frank; S Kary; H Kupper
Journal:  Ann Rheum Dis       Date:  2009-10-07       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.